RheumNow Podcast – FDA Panels Meet on Gout & OP (1.18.19) Save
Dr. Jack Cush reviews the news, articles and FDA Panel discussions from the past week.
- Contraceptive surveys of 164 arthritis pts(138 Rheumatoid;26 Psoriatic) finds one-third (32-35%) using highly effective contraception; 31% using effective methods; but ineffective methods in 35.5% RA & 11.5% PsA and no contraception in 1.5% RA & 23.1% PsA https://t.co/gGBtL2z1FK
- Who thought this was possible? Numbers suggest this is rare. Tis wrong to use this to forge ahead with an unlikely PMR dx in the face of a normal CRP/ESR; but will you go so far as to order the expensive FDG-PET? https://t.co/RTkiUXO7lX
- National registry of lupus nephritis pts w/ ESRD (n=20,974) between 1995-2014 showed that mortality declined from 11.1 to 6.7/100PY; Mortality declined for whites (HR 0.68), blacks (0.67) and Hispanics (0.51) and declined for CVD and infx by 44% & 63% https://t.co/0zDQmLymes
- Combined study of Danbio (Denmark) and ARTIS (Sweden) RA registries showed that in 8987 treatment courses of abatacept, rituximab or tocilizumab there was no difference in Serious infection rates - ranging from 4.7-8.1 SIE/100 Pt Yrs. https://t.co/JpYDeSPdpy
- CDC report 5 Jan 2019: 7 million cases of influenza w/ an estimated 69,000 to 84,000 hospitalized for flu-related illness. H1N1 is the most common strain. Flu activity is widespread in 30 states https://t.co/kLsZjKDJen
- FDA Panel Backs Approval of Romosuzumab for Osteoporosis
- Febuxostat Gets Reprieve from FDA Advisory Panel
- Anakinra for Acute Crystal-Induced Arthritis
- Early Predictive Factors for Scleroderma Renal Crisis
- RheumNow.live
ADD THE FIRST COMMENT
Disclosures
The author has received compensation as an advisor or consultant on this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.